Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 8:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 2,506 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Normal protein Clear all
Completed Phase 2 Interventional

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer

NCT00255749
View directory record Official record
Conditions
Anemia, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
epoetin alfa
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 31, 2026, 8:15 PM EDT
Terminated Phase 2 Interventional Results available

Endocrine Therapy + OSI-906 With or Without Erlotinib for Hormone-Sensitive Metastatic Breast Cancer

NCT01205685
View directory record Official record
Conditions
Hormone-sensitive Metastatic Breast Cancer
Interventions
OSI-906, Erlotinib, Letrozole, Goserelin
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
3
States / cities
Franklin, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

NCT01659151
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
High Dose Interleukin-2 (IL-2), ACT with TIL Infusion, Vemurafenib, Lymphodepletion
Drug · Procedure
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 2 Interventional

Combination Chemotherapy, Bone Marrow or Peripheral Stem Cell Transplantation, and/or Biological Therapy in Treating Patients With Stage III or Stage IV Mantle Cell Lymphoma

NCT00004231
View directory record Official record
Conditions
Lymphoma
Interventions
aldesleukin, filgrastim, recombinant interferon alfa, busulfan, cyclophosphamide, cytarabine, doxorubicin hydrochloride, leucovorin calcium, methotrexate, prednisone, teniposide, vincristine sulfate, allogeneic bone marrow transplantation, autologous bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Results available

A Study of Leuprolide to Treat Prostate Cancer

NCT00626431
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide acetate - Formulation A, Leuprolide acetate - Formulation B
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older · Male only
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
63
States / cities
Birmingham, Alabama • Homewood, Alabama • Anchorage, Alaska + 58 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 3 Interventional

High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia

NCT00002945
View directory record Official record
Conditions
Leukemia
Interventions
aldesleukin, filgrastim, cyclophosphamide, cytarabine, etoposide, idarubicin, melphalan, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
25 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2011
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2012 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 2 Interventional

Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

NCT00003211
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
filgrastim, amifostine trihydrate, cisplatin, cyclophosphamide, vincristine sulfate, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
3 Years to 20 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
2
States / cities
Memphis, Tennessee • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 7, 2012 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 3 Interventional Results available

Early Treatment of Cytokine Storm Syndrome in Covid-19

NCT04362111
View directory record Official record
Conditions
Cytokine Storm, COVID-19
Interventions
Anakinra, Normal saline
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke

NCT02730455
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
natalizumab, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
18
States / cities
Los Angeles, California • Sacramento, California • San Diego, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor

NCT00638898
View directory record Official record
Conditions
Solid Tumor, Adult Central Nervous System Germ Cell Tumor, Adult Rhabdomyosarcoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Soft Tissue Sarcoma, Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Ovarian Mixed Germ Cell Tumor, Previously Untreated Childhood Rhabdomyosarcoma, Recurrent Adult Brain Tumor, Recurrent Adult Soft Tissue Sarcoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Extragonadal Germ Cell Tumor, Recurrent Extragonadal Non-seminomatous Germ Cell Tumor, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Neuroblastoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Wilms Tumor and Other Childhood Kidney Tumors, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
busulfan, melphalan, topotecan hydrochloride, laboratory biomarker analysis, filgrastim, autologous hematopoietic stem cell transplantation, pharmacological study, autologous bone marrow transplantation
Drug · Other · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
6 Months to 40 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2024
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Not applicable Interventional

L-Carnosine for Bipolar I Disorder

NCT00177463
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
L-carnosine
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
3
States / cities
Bridgeville, Pennsylvania • McKeesport, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 11, 2016 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Estrogen Sensitivity and Ovulatory Dysfunction in Obesity

NCT01381016
View directory record Official record
Conditions
Obesity, Infertility
Interventions
Estradiol, Gonadotropin-releasing hormone (GnRH), Progesterone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 42 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 20, 2015 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Not applicable Interventional Results available

Surgical Site Infection With 0.05% Chlorhexidine (CHG) Compared to Triple Antibiotic Irrigation

NCT02395614
View directory record Official record
Conditions
Breast Cancer
Interventions
Chlorhexidine irrigation, triple antibiotic irrigation
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 81 Years · Female only
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 26, 2022 · Synced Oct 31, 2026, 8:15 PM EDT
Completed No phase listed Observational

IL-2 "SELECT" Tissue Collection Protocol in Patients With Advanced Melanoma

NCT01288963
View directory record Official record
Conditions
Malignant Melanoma
Interventions
IL-2
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function

NCT01516047
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Cohort 1, Cohort 2
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
35 Years to 80 Years · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
3
States / cities
Anaheim, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy, SU5416, Radiation Therapy, and Surgery in Treating Patients With Soft Tissue Sarcoma

NCT00023738
View directory record Official record
Conditions
Sarcoma
Interventions
filgrastim, dacarbazine, doxorubicin hydrochloride, ifosfamide, semaxanib, conventional surgery, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
207
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 31, 2026, 8:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

C-reactive Protein and Endothelial Dysfunction in Women With Glucose Intolerance

NCT00589355
View directory record Official record
Conditions
Glucose Intolerance
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Stem Cell Transplant for Inborn Errors of Metabolism

NCT00176904
View directory record Official record
Conditions
Adrenoleukodystrophy, Metachromatic Leukodystrophy, Globoid Cell Leukodystrophy, Gaucher's Disease, Fucosidosis, Wolman Disease, Niemann-Pick Disease, Batten Disease, GM1 Gangliosidosis, Tay Sachs Disease, Sandhoff Disease
Interventions
Stem Cell Transplant, Busulfan, Cyclophosphamide, Antithymocyte Globulin
Procedure · Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2010
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 31, 2026, 8:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Zinc and the Synthesis of Zinc Binding Proteins (Protocol B)

NCT01221129
View directory record Official record
Conditions
Zinc Deficiency
Interventions
Acclimation, Dietary zinc depletion, Dietary zinc repletion
Other
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 35 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 1Phase 2 Interventional

Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia

NCT00004107
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, autologous bone marrow transplantation, peripheral blood stem cell transplantation, indium In 111 monoclonal antibody MN-14, yttrium Y 90 epratuzumab
Biological · Procedure · Radiation
Lead sponsor
Garden State Cancer Center at the Center for Molecular Medicine and Immunology
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
4
States / cities
Belleville, New Jersey • Livingston, New Jersey • Paterson, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2011 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 1 Interventional

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00058292
View directory record Official record
Conditions
Lymphoma
Interventions
filgrastim, rituximab, Carmustine, cytarabine, etoposide, melphalan, peripheral blood stem cell transplantation, yttrium Y 90 ibritumomab tiuxetan
Biological · Drug · Procedure + 1 more
Lead sponsor
Northwestern University
Other
Eligibility
17 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
3
States / cities
Chicago, Illinois • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 31, 2026, 8:15 PM EDT
Enrolling by invitation Phase 4 Interventional Accepts healthy volunteers

Can Intraosseous Antibiotics Improve the Results of Irrigation & Debridement and Prosthetic Retention for PJI?

NCT03713528
View directory record Official record
Conditions
Joint Infection
Interventions
Intraoperative Intraosseous Vancomycin
Drug
Lead sponsor
OrthoCarolina Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
10
States / cities
San Francisco, California • Gainesville, Florida • Weston, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 31, 2026, 8:15 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Overcoming Membrane Transporters to Improve CNS Drug Delivery - Improving Brain Antioxidants After Traumatic Brain Injury

NCT01322009
View directory record Official record
Conditions
Pediatric Traumatic Brain Injury
Interventions
Probenecid and N-acetyl cysteine, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
2 Years to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 31, 2026, 8:15 PM EDT
Not listed Phase 1 Interventional

Biological Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Breast Cancer

NCT00002616
View directory record Official record
Conditions
Breast Cancer
Interventions
aldesleukin, filgrastim, carboplatin, cyclophosphamide, thiotepa, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of Illinois Chicago
Other
Eligibility
Up to 64 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1995
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 31, 2026, 8:15 PM EDT